Cargando…
Trial Watch: Peptide-based anticancer vaccines
Malignant cells express antigens that can be harnessed to elicit anticancer immune responses. One approach to achieve such goal consists in the administration of tumor-associated antigens (TAAs) or peptides thereof as recombinant proteins in the presence of adequate adjuvants. Throughout the past de...
Autores principales: | Pol, Jonathan, Bloy, Norma, Buqué, Aitziber, Eggermont, Alexander, Cremer, Isabelle, Sautès-Fridman, Catherine, Galon, Jérôme, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido, Galluzzi, Lorenzo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4485775/ https://www.ncbi.nlm.nih.gov/pubmed/26137405 http://dx.doi.org/10.4161/2162402X.2014.974411 |
Ejemplares similares
-
Trial Watch: Anticancer radioimmunotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013) -
Trial watch: Peptide vaccines in cancer therapy
por: Vacchelli, Erika, et al.
Publicado: (2012) -
Trial Watch: Peptide vaccines in cancer therapy
por: Aranda, Fernando, et al.
Publicado: (2013) -
Trial Watch: DNA vaccines for cancer therapy
por: Pol, Jonathan, et al.
Publicado: (2014) -
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)